We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Amelia
Harshfield
ah824@cam.ac.uk
Dr
Graham
Murray
gm285@cam.ac.uk
Dr
Graham
Murray
gm285@cam.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Schizophrenia, schizotypal and delusional disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
We aim to develop a longitudinal representative study that will allow researchers to identify ways to help earlier identification, treatment and prevention of emerging psychosis patients. Patients who have had at least one episode of psychosis or identified as being at risk of psychosis will be invited to participate in the study. Controls will also be recruited.
Participants will be invited to give a blood sample, and a researcher will ask them questions from a set of questionnaires. Patients (but not controls) will also be asked to complete questionaires via electronic means (online or via a phone app once launched). They will answer these questions shortly after their initial appointment and at least every six months for a duration of up to 3 years.
If participants are unable to give blood (e.g. for clinical reasons) then saliva may be used instead. If patients do not have access to a smartphone or wish not to use the phone app on their personal phone (once launched), then with agreement with the researcher, the researcher may take on the responsibility of inputting the app data on the patient’s behalf. If patients do not enter information at the six-monthly interval, a researcher may get in touch with them to remind them.
Participants are welcome to withdraw at any point in the study. A full explanation of how their data is managed is provided in the Participant Information Sheet. They may be asked the reason(s) for their withdrawal to improve future studies.
By participating, participants will allow researchers to learn more about the genetic sequence, chemical makeup, protein makeup, and the body’s natural defence system, to facilitate new research to drive improvements in the early diagnosis and treatment of psychosis. This will allow future studies to drive forward preventive approaches and new treatments.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
*Exclusion criteria for cases: Prisoners or in custody of HM Prison Services Inability to complete study measures as assessed by the study team. *Exclusion criteria for controls: All exclusion criteria as set out for cases; and Personal history of psychosis (self-report).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Graham
Murray
gm285@cam.ac.uk
Amelia
Harshfield
ah824@cam.ac.uk
Dr
Graham
Murray
gm285@cam.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by CAMBRIDGESHIRE AND PETERBOROUGH NHS FOUNDATION TRUST and funded by NIHR Oxford Health Biomedical Research Centre .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 61966
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
